This double-blind, randomized, placebo-controlled trial (n=35) will investigate the impact of psilocybin (5–10 mg) on pain perception in fibromyalgia patients.
This within-subject, double-blind, randomized placebo-controlled study will test two low doses of oral psilocybin (5 mg and 10 mg) versus placebo in 35 fibromyalgia patients to assess effects on experimental pain sensitivity (Cold Pressor Test and Pressure Pain Threshold).
Participants attend five visits over five weeks including screening/familiarization, three dosing sessions (placebo, 5 mg, 10 mg, randomized order) with experimental tasks, blood sampling and questionnaires, and a final online follow-up; a brief hypnotic induction is applied before one CPT to test moderation of analgesic response.
Within-subject, randomized crossover: each participant receives placebo, 5 mg and 10 mg psilocybin in randomized order; brief hypnotic induction before second CPT.
Oral capsules; 5 mg and 10 mg arms administered in randomized order
Matching placebo capsule
Brief hypnotic induction aimed at producing analgesia before the second CPT (behavioral intervention)